Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Oncology/Epidemiology
  • Published:

Clinical Oncology/Epidemiology

Serum thyroglobulin as a preclinical tumour marker in subgroups of thyroid cancer

Abstract

Serum samples from a biological serum bank taken several years before the diagnosis of cancer, were analysed for S-Tg and S-TSH in 43 patients with thyroid cancer and compared to 128 healthy controls matched for age, sex, geographical region and time of blood sampling. The main finding was the difference in S-Tg between cases and controls, the highest values being found in sera from cases. Relative risk of thyroid cancer increases with increasing S-Tg levels (the global test giving P less than 0.0005). Extremely high levels were found in 4 cases with follicular and 3 with anaplastic cancers. No such statistically significant difference was found in S-TSH concentration. Possible explanations for the elevated S-Tg observed several years before clinically evident malignant tumour are discussed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thoresen, S., Myking, O., Glattre, E. et al. Serum thyroglobulin as a preclinical tumour marker in subgroups of thyroid cancer. Br J Cancer 57, 105–108 (1988). https://doi.org/10.1038/bjc.1988.19

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1988.19

Search

Quick links